A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., a company based in Edmonton. Aurora has established a special committee to review the unsolicited bid following an announcement by Curaleaf Holdings Inc. outlining their proposal to acquire all shares of Aurora. If successful, the merger would result in a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets.
Curaleaf, headquartered in Stamford, Conn., disclosed that they decided to publicly announce their bid after unsuccessful attempts to negotiate privately with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7, Aurora’s board reportedly declined to engage in discussions with Curaleaf. Boris Jordan, Curaleaf’s CEO, expressed disappointment in Aurora’s lack of engagement and emphasized the strategic value and significant premium of the proposed deal.
Curaleaf’s proposal includes offering Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share. However, Aurora clarified that the financial terms were only detailed in the July 7 letter from Curaleaf, not in the initial communication. Aurora also refuted Curaleaf’s assertion that they refused to consider the offer, indicating ongoing communication between the companies.
Aurora intends to establish a special committee of independent directors to evaluate the proposal’s alignment with the company’s stakeholders’ best interests. While acknowledging Curaleaf’s interest, Aurora cautioned that a deal is not guaranteed, and business operations will continue as usual. Analysts from TD Cowen expressed the opinion that the current offer undervalues Aurora’s long-term potential, citing the company’s market leadership, product portfolio, financial strength, and global regulatory expertise as factors contributing to its intrinsic value.
Jordan highlighted the potential synergies of merging the companies, emphasizing the combination of Curaleaf’s distribution network with Aurora’s international medical cannabis presence. The joint revenue of over $1.5 billion US in the last year and anticipated cost savings of $40 million US per annum further support the rationale behind the proposed acquisition. Jordan emphasized the benefits for both Curaleaf and Aurora shareholders, emphasizing the opportunity for Aurora shareholders to access a broader global platform and benefit from U.S. regulatory developments.